Pharmaceutical

EMA starts review into hair loss drugs about potential link to suicidal thoughts 

The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.

Oct 8, 2024 - 04:00
EMA starts review into hair loss drugs about potential link to suicidal thoughts 
The safety review was requested by the French medicines agency, citing new safety reports that alter the risk profile of finasteride.
Read the original article

Tags:

Previous Article

Neuvivo makes bid to enter ALS arena with immunotherapy candidate

Next Article

Oncolytics targets accelerated approval for oncolytic virus therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast

Morning Rounds: Preterm birth rates vary across the U.S...

Dec 11, 2023

UK negotiates reform for branded drug payment amidst industry dissatisfaction

UK negotiates reform for branded drug payment amidst in...

May 6, 2023

Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch

Listen: Racing for gene therapy, a pioneering approval,...

Aug 17, 2023